Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BLFS 
BioLife Solutions Inc (BLFS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BLFS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -5.32% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.07B USD | Price to earnings Ratio - | 1Y Target Price 31.33 |
Price to earnings Ratio - | 1Y Target Price 31.33 | ||
Volume (30-day avg) 407217 | Beta 2.04 | 52 Weeks Range 14.84 - 29.55 | Updated Date 04/2/2025 |
52 Weeks Range 14.84 - 29.55 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.25 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -24.54% | Operating Margin (TTM) -40.48% |
Management Effectiveness
Return on Assets (TTM) -1.1% | Return on Equity (TTM) -3.32% |
Valuation
Trailing PE - | Forward PE 250 | Enterprise Value 996471444 | Price to Sales(TTM) 13.02 |
Enterprise Value 996471444 | Price to Sales(TTM) 13.02 | ||
Enterprise Value to Revenue 12.11 | Enterprise Value to EBITDA 650.44 | Shares Outstanding 46906800 | Shares Floating 36362490 |
Shares Outstanding 46906800 | Shares Floating 36362490 | ||
Percent Insiders 2.47 | Percent Institutions 101.86 |
Analyst Ratings
Rating 4.8 | Target Price 30.9 | Buy 2 | Strong Buy 8 |
Buy 2 | Strong Buy 8 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
BioLife Solutions Inc
Company Overview
History and Background
BioLife Solutions, Inc. was founded in 1997. It focuses on biopreservation tools and services for cell and gene therapies. Early focus was on media for organ preservation, evolving to a broader range of biopreservation solutions. Key milestones include the introduction of CryoStor and HypoThermosol biopreservation media and strategic acquisitions to expand product offerings.
Core Business Areas
- Biopreservation Media: Development, manufacturing, and marketing of proprietary biopreservation freeze media (CryoStor) and cold storage media (HypoThermosol) to protect cells during freezing and thawing.
- Bioprocessing Freezers: Thawing and freezing controlled rate freezers
- Related Equipment and Services: Other services that complement biopreservation solutions such as custom media formulation.
Leadership and Structure
The leadership team includes the CEO, COO, CFO, and other senior management personnel responsible for various functions. The organizational structure is hierarchical with functional departments such as R&D, Manufacturing, Sales & Marketing, and Finance.
Top Products and Market Share
Key Offerings
- CryoStor: A line of serum-free, animal component-free cryopreservation media used to protect cells during freezing. Competitors include STEMCELL Technologies and Corning. Market Share is approximately 40% within the cryopreservation media market.
- HypoThermosol: A family of hypothermic storage and shipping media used to extend the viability of cells, tissues, and organs at refrigerated temperatures. Competitors include STEMCELL Technologies and Corning. Market Share is approximately 45% within the hypothermic storage media market.
Market Dynamics
Industry Overview
The biopreservation market is growing due to increased demand for cell and gene therapies, regenerative medicine, and biobanking. The market includes solutions such as cryopreservation, freeze-drying, and hypothermic storage. Factors such as regulatory requirements, advances in technology, and growing research investments drive market growth.
Positioning
BioLife Solutions is positioned as a leading provider of biopreservation media and related tools for the cell and gene therapy market. Its competitive advantages include proprietary formulations, established reputation, and strategic relationships with key players in the industry.
Total Addressable Market (TAM)
The TAM for biopreservation is estimated at $2 billion by 2028. BioLife Solutions is targeting a significant portion of this market through its biopreservation media and related solutions.
Upturn SWOT Analysis
Strengths
- Proprietary biopreservation formulations
- Established reputation and brand recognition
- Strategic relationships with cell and gene therapy companies
- Strong intellectual property portfolio
Weaknesses
- Dependence on the growth of the cell and gene therapy market
- Potential for pricing pressure from competitors
- Reliance on key suppliers for raw materials
Opportunities
- Expanding product portfolio to include new biopreservation technologies
- Entering new geographic markets
- Acquiring complementary businesses
- Collaborating with research institutions
Threats
- Competition from established players and new entrants
- Changes in regulatory requirements
- Economic downturn impacting research funding
- Technological disruptions
Competitors and Market Share
Key Competitors
- STML
- THER
- CCRD
Competitive Landscape
BioLife Solutions faces competition from established players and new entrants in the biopreservation market. The company's advantages include proprietary formulations and established reputation. Disadvantages could include reliance on the growth of the cell and gene therapy market.
Major Acquisitions
SAVSU Technologies
- Year: 2020
- Acquisition Price (USD millions): 93
- Strategic Rationale: Expanded capabilities in cold chain management and temperature monitoring.
Global Cooling
- Year: 2021
- Acquisition Price (USD millions): 84
- Strategic Rationale: Adds Stirling Ultracold freezers to expand biopreservation product line.
Barkey
- Year: 2021
- Acquisition Price (USD millions): 114
- Strategic Rationale: Adds Barkey thawing equipment and solutions to expand biopreservation product line.
Growth Trajectory and Initiatives
Historical Growth: BioLife Solutions has experienced growth through organic sales and strategic acquisitions.
Future Projections: Future growth is projected based on the continued expansion of the cell and gene therapy market.
Recent Initiatives: Recent initiatives include acquisitions to expand product offerings, investments in R&D, and expansion into new geographic markets.
Summary
BioLife Solutions is a key player in the biopreservation market, driven by the expansion of cell and gene therapies. Strengths include its proprietary solutions and strategic relationships, while weaknesses involve reliance on market growth and competition. Future growth is expected from strategic acquisitions and market penetration, but threats include evolving regulatory landscape. The company's financial performance has been unstable.
Similar Companies
CCRD
CoreCard Corp
CCRD
CoreCard Corp
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q), Company Website, Investor Presentations, Market Research Reports, Analyst Reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change. Market Share Comparison is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioLife Solutions Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 1989-11-22 | CEO & Chairman Mr. Roderick de Greef | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 159 | Website https://www.biolifesolutions.com |
Full time employees 159 | Website https://www.biolifesolutions.com | ||
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.